Comparative Pharmacology
Head-to-head clinical analysis: KOMBIGLYZE XR versus SITAGLIPTIN PHOSPHATE METFORMIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KOMBIGLYZE XR versus SITAGLIPTIN PHOSPHATE METFORMIN HYDROCHLORIDE.
KOMBIGLYZE XR vs SITAGLIPTIN PHOSPHATE; METFORMIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KOMBIGLYZE XR is a combination of saxagliptin, a DPP-4 inhibitor, and metformin, an AMPK activator. Saxagliptin increases incretin levels (GLP-1, GIP) by inhibiting DPP-4, leading to increased insulin release and decreased glucagon secretion. Metformin decreases hepatic gluconeogenesis and increases peripheral insulin sensitivity.
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels (GLP-1, GIP), enhancing glucose-dependent insulin secretion and decreasing glucagon secretion. Metformin is a biguanide that reduces hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity.
One tablet orally once daily with food; available strengths: saxagliptin 5 mg/metformin extended-release 500 mg, saxagliptin 5 mg/metformin extended-release 1000 mg. Titrate based on glycemic response and tolerability.
Oral, 50 mg sitagliptin/500 mg metformin twice daily or 50 mg sitagliptin/1000 mg metformin twice daily, individually titrated based on glycemic response and tolerability. Maximum daily dose: sitagliptin 100 mg, metformin 2000 mg.
None Documented
None Documented
Terminal elimination half-life for saxagliptin is 2.5 hours and for its active metabolite is 3.1 hours; clinical context: no significant accumulation at steady state.
Sitagliptin: 12.4 h; metformin: 6.2 h (prolonged in renal impairment).
Renal excretion of unchanged saxagliptin (24%) and its active metabolite 5-hydroxy saxagliptin (22%); fecal excretion of parent (0.3%) and metabolite (6%); total renal elimination accounts for approximately 75% of the administered dose.
Renal: sitagliptin ~87% unchanged in urine; metformin ~90% unchanged in urine. Biliary/fecal: minimal.
Category C
Category A/B
DPP-4 Inhibitor + Biguanide Combination
DPP-4 Inhibitor